Validation, by mass spectrometry (MS), of predicted neoantigens in urinary extracellular vesicles coming from cancer prostate patients. We performed MS on PC3, LNCaP and HCT116 cells and compared MS-detected peptides with established PC3 lncRNA peptides, peptides from lncRNAs upregulated in uEVs and Swiss prot databanks.